Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround

15.11.24 15:35 Uhr

Werte in diesem Artikel
Aktien

0,44 USD -0,00 USD -0,58%

Indizes

19.003,7 PKT 31,2 PKT 0,16%

A downtrend has been apparent in Agenus (AGEN) lately with too much selling pressure. The stock has declined 39.4% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.Why AGEN Could Bounce Back Before LongThe heavy selling of AGEN shares appears to be in the process of exhausting itself, as indicated by its RSI reading of 17.56. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand.The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for AGEN has increased 38.9%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.Moreover, AGEN currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Must-See: Solar Stocks Poised to SkyrocketThe solar industry stands to bounce back as tech companies and the economy transition away from fossil fuels to power the AI boom.Trillions of dollars will be invested in clean energy over the coming years – and analysts predict solar will account for 80% of the renewable energy expansion. This creates an outsized opportunity to profit in the near-term and for years to come. But you have to pick the right stocks to get into.Discover Zacks’ hottest solar stock recommendation FREE.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Agenus

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Agenus

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Agenus Inc

Analysen zu Agenus Inc

DatumRatingAnalyst
22.04.2019Agenus BuyB. Riley FBR
28.10.2016Agenus NeutralH.C. Wainwright & Co.
27.10.2016Agenus BuyMaxim Group
11.03.2016Agenus BuyMaxim Group
27.10.2015Agenus HoldMaxim Group
DatumRatingAnalyst
22.04.2019Agenus BuyB. Riley FBR
27.10.2016Agenus BuyMaxim Group
11.03.2016Agenus BuyMaxim Group
27.07.2015Agenus BuyMLV Capital
11.06.2015Agenus OutperformOppenheimer & Co. Inc.
DatumRatingAnalyst
28.10.2016Agenus NeutralH.C. Wainwright & Co.
27.10.2015Agenus HoldMaxim Group
11.10.2005Update Antigenics Inc: HoldStanford Research
07.06.2005Update Antigenics Inc: UnderweightPrudential Securities
DatumRatingAnalyst
27.03.2006Update Antigenics Inc: ReduceUBS
18.10.2005Update Antigenics Inc: SellBanc of America Sec.
07.06.2005Antigenics underweightPrudential Financial

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Agenus Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"